Cantor Fitzgerald Brokers Cut Earnings Estimates for Alumis

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Alumis in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($5.36) per share for the year, down from their prior estimate of ($4.13). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

ALMS has been the topic of several other reports. Oppenheimer initiated coverage on shares of Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (down previously from $19.00) on shares of Alumis in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Alumis presently has a consensus rating of “Buy” and an average target price of $26.00.

Alumis Price Performance

Shares of ALMS opened at $4.00 on Monday. The company’s 50-day moving average is $5.55 and its 200-day moving average is $8.43. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new position in Alumis in the 3rd quarter valued at about $27,000. MetLife Investment Management LLC acquired a new stake in shares of Alumis during the 3rd quarter worth approximately $89,000. Wells Fargo & Company MN increased its stake in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after acquiring an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Alumis during the fourth quarter valued at approximately $79,000. Finally, Marshall Wace LLP bought a new stake in Alumis during the fourth quarter worth $108,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.